Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT02784834 · ClinicalTrials.gov registry record · Phase 1
Dimethylfumarate (DMF) in Relapsed/Refractory CLL/SLL
A Phase 1 study, sponsored by Michael Choi.
- Terminated
- Registry status
- Phase 1
- Development phase
- 2
- Enrollment target
NCT02784834: Clinical Trial Phase 1 study, sponsored by Michael Choi.
NCT02784834 is a Phase 1 study that was terminated before completion, run by Michael Choi. The registered enrollment target is 2 participants, below the 60-participant average among 29,502 other Phase 1 trials with a reported enrollment target (97% lower). According to ClinicalTrials.gov, the official US trial registry.
The verdict
NCT02784834, a Phase 1 study, was terminated before completion, sponsored by Michael Choi.
- TERMINATED
- Registry status
- Phase 1
- Development phase
- 2 participants
- Enrollment target
Study Summary
The purpose of the study is to investigate the safety of the investigational drug called dimethylfumarate (DMF). DMF is a type of drug called an immunomodulatory drug. This drug is approved by the United States (U.S.) Food and Drug Administration (FDA) as a treatment for patient with multiple sclerosis. Although there is evidence from tests on laboratory animals that DMF can decrease the number of CLL cells, we do not know if this will work in humans with CLL. This drug will be given to humans with CLL for the first time in this study. Therefore, the goal of this study is to see if DMF is safe and tolerable in study participants. Participants will be evaluated to find out what effects (good and bad) DMF has on the body and see how long the drug stays in the body.
Primary Outcome
The incidence of dose limiting toxicities (DLTs) will be used to define the maximum tolerated dose or biologically active dose for potential phase 2 studies.
Interventions
- DRUG dimethyl fumarate
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 2 participants |
| Start Date | 2016-06 |
| Est. Completion | 2019-02 |
| Phase | Phase 1 |
Why NCT02784834 stopped before completion
NCT02784834 is an interventional study that assigns participants to a tested intervention. The registry caps enrollment at 2 participants, a relatively small participant target, below the 60-participant average among 29,502 other Phase 1 trials with a reported enrollment target (97% lower).
The record links to 0 conditions, and to 1 intervention - of which dimethyl fumarate is the first listed.
NCT02784834 does not publish any study locations in the registry export this page uses.
Frequently Asked Questions
What is clinical trial NCT02784834 about?
NCT02784834 is a clinical study titled "Dimethylfumarate (DMF) in Relapsed/Refractory CLL/SLL". The purpose of the study is to investigate the safety of the investigational drug called dimethylfumarate (DMF). DMF is a type of drug called an immunomodulatory drug. This drug is approved by the United States (U.S.) Food and Drug Administration (FDA) as a treatment for patient with multiple sclero...
What is the current status of trial NCT02784834?
This trial is currently terminated. It is a Phase 1 study. The enrollment target is 2 participants. The study started on 2016-06. Estimated completion is 2019-02.
What interventions are being tested in trial NCT02784834?
The interventions under investigation include: dimethyl fumarate (DRUG).
Who is sponsoring clinical trial NCT02784834?
This trial is sponsored by Michael Choi, which has 2 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
How this trial's enrollment target compares
Where NCT02784834's enrollment target sits among peer trials
2 2000th of 2000 the lowest of 2,000 other Phase 1 trials
participants (enrollment target), bucketed by value
Each bar is a band; taller bars hold more other Phase 1 trials. The dashed line + filled bar mark this entry. Hover or tap any bar for its full count and share, and where it sits relative to this entry.
Source ClinicalTrials.gov registry export · 2026-08-08
Nationwide trials with similar profiles
Cross-condition peers matched on enrollment target and registry start date, not the same-condition list above.
Similar registry start date
- NCT05988463 · started 2027-01-01 · Phase 1
Dose-Escalation Study of Artesunate Patients With IPF
- NCT07219706 · started 2026-12-10 · NA
Dietary Fiber and Time Restricted Eating
- NCT02831335 · started 2026-12-01
Technical Development of Multi-Parametric Renocerebral MRI
- NCT05962346 · started 2026-12 · NA
Fetal Endoscopic Tracheal Occlusion for Congenital Diaphragmatic Hernia